Clinical trial NCT01672476 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: placebo, valsartan, fimasartan
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1
Eligibility criteria:

        Inclusion Criteria:

          1. Subjects who agreed to participate in this clinical trial and submitted the written
             informed consent

          2. Subjects aged 20 to 75 years

          3. Essential hypertension patients who are measured more 90mmHg, less than 110mmHg of
             sitting diastolic blood pressure(SiDBP) at baseline(Day 0)

          4. Subject who considered to understand this clinical trial, be cooperative,and able to
             be followed-up whole of the clinical trial period

        Exclusion Criteria:

          1. Severe hypertension patients: more 110mmHg of mean SiDBP and/or more 185mmHg of mean
             Sitting systolic blood pressure(SiSBP)

          2. Patients with orthostatic hypotension who has sign and symptom

          3. Patients with secondary hypertension

          4. Patients who are measured the difference of mean blood pressure of one arm under SiDBP
             10mmHg or SiSBP 20mmHg at screening and baseline visit

          5. Patients who cannot stop administration of hypertension medication through the
             clinical trial period, and can take any other hypertension medication except
             investigational drugs

          6. Patients with significant investigations-abnormal renal function (Creatinine more 1.5
             times than upper limit of normal), abnormal liver function(AST, ALT more 2 times than
             upper limit of normal), severe fatty liver disease needed medication

          7. Patients with clinically significant investigations in laboratory test of screening
             visit

          8. Patients with surgical and medical disease that is able to be affect to absorption,
             distribution, metabolism and excretion

          9. Patients with severe insulin dependent or uncontrolled diabetes mellitus (HbA1c>9,
             regimen change of oral hypoglycemic agent, using insulin)

         10. Patients with severe heart disease, ischemic heart disease within 6 months, peripheral
             vascular disease, Percutaneous transluminal coronary angiography(PTCA), Coronary
             artery bypass graft(CABG)

         11. Patients with significant ventricular tachycardia, atrial fibrillation, atrial flutter
             or other significant arrhythmia

         12. Patients with hypertrophic obstructive cardiomyopathy, severe obstructive coronary
             artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral
             valve disease

         13. Patients with severe cerebrovascular disease

         14. Patients with wasting disease, autoimmune disease, connective tissue disease at
             present and/or previous

         15. Patients with known severe or malignancy retinopathy

         16. Patients with hepatitis B or C or HIV positive reaction

         17. Patients with the medical histories of malignant tumor within 5 years,except local
             basal cell carcinoma of the skin

         18. Patients who have a story or evidence of alcohol or drug abuse within 2 years

         19. Patients with history of allergic reaction to any angiotensin II antagonist

         20. Patients with any chronic inflammation disease needed to chronic inflammation therapy

         21. Childbearing and breast-feeding women

         22. Female who plan to become pregnancy or have a possibility of pregnancy but don't
             prevent conception with acknowledged methods

         23. Patients who took medicine within 12 weeks from screening visit or is going on the
             progress of other clinical trial

         24. Patients with significant investigations-Hypokalemia(Less than 3.5 mmol/L),
             Hyperkalemia(exceeded 5.5 mmol/L)

         25. Patients with sodium ion or body fluid is deplated and not able to correct

         26. Subject who are judged unsuitable to participate in this clinical trial by
             investigator